High Expression of PDIA4 Contributes to Poor Prognosis in Glioma

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Glioma is a primary brain tumor with variable prognosis.
• Identifying reliable prognostic biomarkers is crucial for effective glioma management.
• Protein disulfide isomerase A4 (PDIA4) has shown altered expression in various cancers.

Purpose of the Study:

• To investigate the expression levels of PDIA4 in glioma.
• To evaluate the prognostic value of PDIA4 in glioma patients.
• To explore PDIA4 as a potential therapeutic target and prognostic indicator.

Main Methods:

• Analysis of PDIA4 expression in tumor vs. normal tissues using the GEPIA2 database.
• Retrospective clinical data analysis of 118 glioma patients.
• Immunofluorescence to assess PDIA4 localization and expression in glioma tissues.
• Correlation analysis between PDIA4 expression and clinicopathological features, including survival.

Main Results:

• PDIA4 expression was significantly higher in glioma tissues compared to normal brain tissues.
• PDIA4 expression positively correlated with patient age and WHO tumor grade.
• High PDIA4 expression was associated with significantly lower overall survival rates in glioma patients, particularly in low-grade gliomas.
• Multivariate analysis identified elevated PDIA4 expression as an independent prognostic factor for adverse outcomes.

Conclusions:

• PDIA4 is upregulated in gliomas and serves as a significant independent prognostic biomarker.
• Elevated PDIA4 expression is linked to unfavorable outcomes in glioma patients.
• PDIA4 holds potential as a therapeutic target and prognostic indicator in glioma management.